Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
NEWTON, Mass., April 05, 2016 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming 15th Annual Needham Healthcare Conference in New York City on Tuesday, April 12, 2016 at 8:40 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at http://investors.karyopharm.com/events.cfm. A replay of the webcast will be archived on the company's website for 30 days following the presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.
Contact: Justin Renz (617) 658-0574 [email protected] Gina Nugent (617) 460-3579 [email protected]
